China Life eyes biotech in healthcare investment push
The biggest Chinese insurer by assets sees Hong Kong's new listing regime as beneficial as the firm looks to build its private equity exposure to the healthcare sector.
China Life is becoming increasingly bullish on healthcare investments now that Hong Kong’s new listing rules have made it easier for up-and-coming biotechnology firms to list on the stock exchange, according to a senior executive at the biggest mainland insurer.
Sign in to read on!
Registered users get 2 free articles in 30 days.
Subscribers have full unlimited access to AsianInvestor
Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.
¬ Haymarket Media Limited. All rights reserved.